Article

FDA Approves First Biosimilar for Cancer Treatment Highlights SPT Week in Review

Top news of the week from Specialty Pharmacy Times.

5. Curing AIDS, The Time Is Now: Gene-Editing Technology May Eliminate HIV

Company harnesses CRISPR-based gene editing technology as it enters human clinical trials to treat HIV. Read more…

4. Herpes Virus-Immunotherapy Combo Improves Melanoma Treatment

Patients with drug-resistant melanoma treated with a herpes virus-pembrolizumab drug combination showed a complete or partial response. Read more…

3. Microfluidic Device Tracks Long-term Evolution of Cancer Cells to Gain Insight into Metastasis

Device may reveal how to stop cancer cells from spreading. Read more…

2. Herceptin Biosimilar Demonstrates Equivalence in Comparative Phase 3 Study

Investigational trastuzumab biosimilar shows promise as potential lower cost treatment option to Herceptin for breast cancer and gastric cancer. Read more…

1. FDA Approves First Biosimilar for Treatment of Cancer

Bevacizumab-awwb, a biosimilar to Avastin, approved to treat several cancer types. Read more…

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards